Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被Kk采纳,获得10
刚刚
华仔的应助被喵喵采纳,获得10
刚刚
刚刚
刚刚
852的应助被东起欧采纳,获得10
1秒前
HOH完成签到,获得积分10
1秒前
爱学习的应助被无奈平灵采纳,获得10
1秒前
lifenghou完成签到 ,获得积分10
2秒前
英俊的铭的应助被面包树采纳,获得10
2秒前
我要增肌发布了新的文献求助10
2秒前
ml261109完成签到,获得积分10
2秒前
大模型的应助被小七采纳,获得10
3秒前
开朗的骁发布了新的文献求助10
3秒前
晴朗完成签到,获得积分10
4秒前
我不到啊完成签到 ,获得积分10
4秒前
4秒前
4秒前
共享精神的应助被369ninja采纳,获得10
5秒前
5秒前
5秒前
5秒前
Liu关闭了Liu的文献求助
5秒前
搜集达人的应助被郑郑采纳,获得10
6秒前
梅耀寰发布了新的文献求助10
6秒前
6秒前
带VS和发布了新的文献求助10
6秒前
11完成签到,获得积分10
7秒前
初(*^▽^*)心的应助被lilith采纳,获得10
7秒前
欢喜夏天完成签到,获得积分10
7秒前
蒸蛋发布了新的文献求助10
8秒前
李爱国的应助被tt采纳,获得10
8秒前
瑞龙老师完成签到,获得积分10
8秒前
8秒前
8秒前
王明发布了新的文献求助30
8秒前
RuiXu发布了新的文献求助10
9秒前
9秒前
9秒前
9秒前
zhaowenxian完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Modern Artificial Intelligence 1000
Особенности технологий и методов информационно-психологических войн СССР с Великобританией и США в период 1939-1953 гг 1000
Das Matthäusevangelium: Kapitel 1:1–17 1000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8135204
求助须知:如何正确求助?哪些是违规求助? 9536590
关于积分的说明 21618351
捐赠科研通 7717959
什么是DOI,文献DOI怎么找? 3419478
关于科研通互助平台的介绍 2544778
邀请新用户注册赠送积分活动 2461180